Abera Bioscience Past Earnings Performance
Past criteria checks 0/6
Abera Bioscience's earnings have been declining at an average annual rate of -21.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 60.6% per year.
Key information
-21.3%
Earnings growth rate
-8.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 60.6% |
| Return on equity | -43.6% |
| Net Margin | -29.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Abera Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 13 | -4 | 16 | 0 |
| 30 Jun 24 | 9 | -8 | 17 | 0 |
| 31 Mar 24 | 5 | -13 | 18 | 0 |
| 31 Dec 23 | 3 | -17 | 19 | 0 |
| 30 Sep 23 | 0 | -19 | 19 | 0 |
| 30 Jun 23 | 1 | -19 | 20 | 0 |
| 31 Mar 23 | 1 | -20 | 21 | 0 |
| 31 Dec 22 | 2 | -19 | 21 | 0 |
| 30 Sep 22 | 2 | -17 | 20 | 0 |
| 30 Jun 22 | 2 | -15 | 17 | 0 |
| 31 Mar 22 | 1 | -11 | 12 | 0 |
| 31 Dec 21 | 1 | -9 | 10 | 0 |
| 30 Sep 21 | 1 | -8 | 9 | 0 |
| 30 Jun 21 | 1 | -7 | 8 | 0 |
| 31 Mar 21 | 0 | -6 | 6 | 0 |
| 31 Dec 20 | 1 | -4 | 4 | 0 |
| 30 Nov 20 | 1 | -3 | 4 | 0 |
| 31 Dec 19 | 2 | -2 | 4 | 0 |
| 31 Dec 18 | 2 | -3 | 5 | 0 |
| 31 Dec 17 | 1 | -2 | 2 | 0 |
Quality Earnings: 8WK is currently unprofitable.
Growing Profit Margin: 8WK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8WK is unprofitable, and losses have increased over the past 5 years at a rate of 21.3% per year.
Accelerating Growth: Unable to compare 8WK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8WK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 8WK has a negative Return on Equity (-43.62%), as it is currently unprofitable.